Clinical Trial Update: GATEWAY: A Phase 2a Study of PORT-77 in Adults With Erythropoietic Protoporphyria [Phase 2]

View source ↗

Summary

A Phase 2a clinical trial update for PORT-77 in adults with erythropoietic protoporphyria, currently enrolling by invitation.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Erythropoietic Protoporphyria

Drugs mentioned

• PORT-77

Snippet

Sponsor: Portal Therapeutics, Inc. | Conditions: Erythropoietic Protoporphyria (EPP) | Phase 2 | Status: ENROLLING_BY_INVITATION